These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 20872215)

  • 1. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in the pharmacotherapeutic management of osteoporosis.
    Close P; Neuprez A; Reginster JY
    Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer drug treatments: their effects on fracture prevention.
    Geusens P; Reid D
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):983-9. PubMed ID: 16301192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic skeletal therapy for osteoporosis.
    Girotra M; Rubin MR; Bilezikian JP
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):745-54. PubMed ID: 17117299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to manage postmenopausal osteoporosis?
    Body JJ
    Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET; Steel SA; Aye M; Doherty SM
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.
    Valverde P
    Curr Med Chem; 2008; 15(3):284-304. PubMed ID: 18288984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
    Quesada-Gómez JM; Muschitz C; Gómez-Reino J; Greisen H; Andersen HS; Dimai HP
    Osteoporos Int; 2011 Sep; 22(9):2529-37. PubMed ID: 21052638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anabolic agents: a new chapter in the management of osteoporosis.
    Khan AW; Khan A
    J Obstet Gynaecol Can; 2006 Feb; 28(2):136-41. PubMed ID: 16643716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualizing osteoporosis therapy.
    Silverman S; Christiansen C
    Osteoporos Int; 2012 Mar; 23(3):797-809. PubMed ID: 22218417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
    Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
    Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
    Jobke B; Burghardt AJ; Muche B; Hahn M; Semler J; Amling M; Majumdar S; Busse B
    PLoS One; 2011; 6(8):e23638. PubMed ID: 21858188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of osteoporosis medications on bone quality.
    Benhamou CL
    Joint Bone Spine; 2007 Jan; 74(1):39-47. PubMed ID: 17196423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis: non-hormonal treatment.
    Rizzoli R
    Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
    Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.